Antibody to Hepatitis C Virus in Risk Groups in Canada
The prevalence of antibodies against hepatitis C virus (HCV) was studied in hemophiliacs, hemodialysis patients, intravenous drug abusers, female prisoners, homosexuals, individuals with no markers of recent hepatitis A or B virus infections and normal individuals (federal public servants), by an en...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/710476 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832566594702671872 |
|---|---|
| author | RK Chaudhary Theresa Mo |
| author_facet | RK Chaudhary Theresa Mo |
| author_sort | RK Chaudhary |
| collection | DOAJ |
| description | The prevalence of antibodies against hepatitis C virus (HCV) was studied in hemophiliacs, hemodialysis patients, intravenous drug abusers, female prisoners, homosexuals, individuals with no markers of recent hepatitis A or B virus infections and normal individuals (federal public servants), by an enzyme immunoassay (Ortho Diagnostic Systems Inc). Repeat positive samples were further tested by recombinant immunoblot assay (RIBA) HCV (Chiron Corp, California). The number of samples positive for antibodies to HCV (anti-HCV) was higher with enzyme immunoassay than by RIBA HCV in most cases. A high prevalence of anti-HCV was detected in hemophiliacs by both enzyme immunoassay (68.8%) and RIBA HCV (53.7%). Among intravenous drug abusers and female prisoners the prevalence rates for anti-HCV were 42.8% and 29.8%, respectively, by RIBA HCV; the results with enzyme immunoassay were only slightly higher. The prevalence rate was also high by both tests (54.2%) in hemodialysis patients’ sera taken during 1980–82, when many cases of non-A,non-B hepatitis were suspected in this group. In contrast, only 14.1% of sera taken during 1990 were positive by RIBA HCV. In individuals with no markers of recent hepatitis A or B infections, 13.4% were positive by enzyme immunoassay, whereas only 4.5% were reactive by RIBA HCV. The lowest prevalence was seen in homosexuals (2.3%) and normal individuals (1.2%) by RIBA HCV. These results indicate a high prevalence of anti-HCV in high risk groups tested in Canada. |
| format | Article |
| id | doaj-art-1159be304b44468592184d929c237331 |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 1992-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-1159be304b44468592184d929c2373312025-02-03T01:03:39ZengWileyCanadian Journal of Infectious Diseases1180-23321992-01-0131272910.1155/1992/710476Antibody to Hepatitis C Virus in Risk Groups in CanadaRK Chaudhary0Theresa Mo1Laboratory for Viral Hepatitis, National Laboratory for Special Pathogens, Laboratory Centre for Disease Control, Health and Welfare Canada, Ottawa, Ontario, CanadaLaboratory for Viral Hepatitis, National Laboratory for Special Pathogens, Laboratory Centre for Disease Control, Health and Welfare Canada, Ottawa, Ontario, CanadaThe prevalence of antibodies against hepatitis C virus (HCV) was studied in hemophiliacs, hemodialysis patients, intravenous drug abusers, female prisoners, homosexuals, individuals with no markers of recent hepatitis A or B virus infections and normal individuals (federal public servants), by an enzyme immunoassay (Ortho Diagnostic Systems Inc). Repeat positive samples were further tested by recombinant immunoblot assay (RIBA) HCV (Chiron Corp, California). The number of samples positive for antibodies to HCV (anti-HCV) was higher with enzyme immunoassay than by RIBA HCV in most cases. A high prevalence of anti-HCV was detected in hemophiliacs by both enzyme immunoassay (68.8%) and RIBA HCV (53.7%). Among intravenous drug abusers and female prisoners the prevalence rates for anti-HCV were 42.8% and 29.8%, respectively, by RIBA HCV; the results with enzyme immunoassay were only slightly higher. The prevalence rate was also high by both tests (54.2%) in hemodialysis patients’ sera taken during 1980–82, when many cases of non-A,non-B hepatitis were suspected in this group. In contrast, only 14.1% of sera taken during 1990 were positive by RIBA HCV. In individuals with no markers of recent hepatitis A or B infections, 13.4% were positive by enzyme immunoassay, whereas only 4.5% were reactive by RIBA HCV. The lowest prevalence was seen in homosexuals (2.3%) and normal individuals (1.2%) by RIBA HCV. These results indicate a high prevalence of anti-HCV in high risk groups tested in Canada.http://dx.doi.org/10.1155/1992/710476 |
| spellingShingle | RK Chaudhary Theresa Mo Antibody to Hepatitis C Virus in Risk Groups in Canada Canadian Journal of Infectious Diseases |
| title | Antibody to Hepatitis C Virus in Risk Groups in Canada |
| title_full | Antibody to Hepatitis C Virus in Risk Groups in Canada |
| title_fullStr | Antibody to Hepatitis C Virus in Risk Groups in Canada |
| title_full_unstemmed | Antibody to Hepatitis C Virus in Risk Groups in Canada |
| title_short | Antibody to Hepatitis C Virus in Risk Groups in Canada |
| title_sort | antibody to hepatitis c virus in risk groups in canada |
| url | http://dx.doi.org/10.1155/1992/710476 |
| work_keys_str_mv | AT rkchaudhary antibodytohepatitiscvirusinriskgroupsincanada AT theresamo antibodytohepatitiscvirusinriskgroupsincanada |